This paper reviews the incidence, pathogenetic mechanisms and management strategies of
diabetes mellitus in patients with human immunodeficiency virus (HIV) and acquired …

Approximately two years after the introduction of highly active antiretroviral therapy for the
treatment of HIV infection, body shape changes and metabolic abnormalities were …

OBJECTIVE—Metabolic syndrome is a cluster of risk factors for cardiovascular disease and
type 2 diabetes. Definitions exist to identify those “at risk.” Treatment of HIV infection with …

The use of combination antiretroviral therapy (CART) in HIV‐infected patients has resulted in
a dramatic decline in AIDS‐related mortality. However, mortality due to non‐AIDS …

Use of highly active antiretroviral therapy (HAART) for the treatment of human
immunodeficiency virus (HIV) infection is associated with the development of cardiovascular …

Highly active antiretroviral therapy (HAART) regimens, especially those including protease
inhibitors have been shown to cause, in a high proportion of HIV-infected patients, a …

The use of highly active antiretroviral therapy (HAART) in HIV-1 infection confers
immunological and survival advantages, at the cost of induction of significant metabolic …

The prevalence and incidence of insulin resistance and type 2 diabetes mellitus (DM) are
higher in people treated for human immunodeficiency virus-1 (HIV) infection than in the …

Highly active antiretroviral therapy in Human Immunodeficiency Virus (HIV) has been
associated with lipodystrophy, insulin resistance and atherosclerosis. We investigated the …

Studies published before the introduction of highly active antiretroviral therapy (HAART)
have tracked the incidence and course of human immunodeficiency virus (HIV) infection in …